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Background: Adrenocortical carcinomas (ACCs) are among the most common childhood cancers occurring in infants
affected with the Li-Fraumeni and Li- Fraumeni-like (LFS/LFL) syndromes, which are caused by dominant germline
mutations in the TP53 gene. In Brazil, a particular mutation, occurring in the tetramerisation domain of the gene, p.R337H,
is exceedingly common due to a founder effect and is strongly associated with ACC. In this report, we describe the
phenotype and long-term clinical follow-up of a female child diagnosed with ACC and homozygous for the TP53 p.R337H
founder mutation.
Case presentation: At age 11 months, the patient was diagnosed with a virilising anaplastic adrenal cortical tumour,
which was completely excised without disturbing the adrenal capsule. Family history was consistent with an LFL tumour
pattern, and genotyping identified the TP53 p.R337H mutation in both alleles in genomic DNA from lymphocytes and
fibroblasts. Haplotype analysis confirmed the occurrence of the mutation in the same founder haplotype previously
described in other Brazilian patients. No other germline or somatic TP53 mutations or rearrangements were identified. At
age 9 years, the child was asymptomatic and had no evidence of endocrine derangements. Full body and brain magnetic
resonance imaging (MRI) failed to detect any suspicious proliferative lesions, and cardiopulmonary exercise testing results
were within the normal reference for the child’s age, ruling out a major exercise capacity deficiency.
Conclusion: This is the first clinical and aerobic functional capacity documentation of a patient who carries two mutant
TP53 alleles and no wild-type allele. Our results support the hypothesis that TP53 p.R337H, the most common TP53
mutation ever described in any population, is a conditional mutant. Furthermore, our observations over a long period of
clinical follow-up suggest that TP53 p.R337H homozygotes do not have a more severe disease phenotype than do
heterozygote carriers of the same mutation. Patients with the homozygous TP53 p.R337H genotype will require careful
surveillance for lifetime cancer risk and for effects on metabolic capacity later in life.Background
Li-Fraumeni syndrome (LFS; OMIM# 151623) is an
autosomal dominant disorder that predisposes carriers
to multiple, early-onset cancers that are difficult to treat
and often lethal. The most common childhood and ado-
lescent cancers occurring in the classical form of the* Correspondence: pprolla@gmail.com
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Leukaemia and brain tumours occur throughout child-
hood and young adulthood, whereas adrenal cortical car-
cinomas (ACC) and choroid plexus carcinoma occur
primarily in infancy. In young adults, breast cancer is
the most common malignancy. Other tumours observed
in LFS patients include colorectal, lung, gastric, pancre-
atic and prostate cancers, as well as melanoma and
lymphoma [1-3]. Variant forms of the disease, observed
in families with tumours of the LFS spectrum, which re-
semble but do not meet the strict criteria for LFStral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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like (LFL) syndrome [1,4].
The only known genetic defect associated with LFS
and LFL is the inheritance of a mutation in the tumour
suppressor gene TP53 [4,5]. Mutations occur in up to
80% of the classical forms of LFS. TP53 encodes a 53 kD
nuclear phosphoprotein, p53, that acts as a growth suppres-
sor transcription factor, which is inactivated by somatic mu-
tations in many forms of cancer. The most frequent TP53
germline mutations are missense substitutions that cluster
in highly conserved regions of the DNA-binding domain
of the protein (codons 125-300), with hotspots at highly
mutable CpG motifs that are also found in somatic muta-
tions in sporadic cancers. In Brazil, a particular mutation
has been reported in a significant proportion of the LFS
families presenting germline TP53 mutations. This muta-
tion, p.R337H (c.1010 G >A, genomic nucleotide number
16901; CGC to CAC at codon 337), occurs in exon 10 and
was initially identified in Brazilian children with ACC and
no documented familial history of other cancers [6,7]. The
arginine residue at codon 337 is part of an alpha-helix motif
involved in p53 oligomerisation. Structural studies on the
p53 oligomerisation domain have shown that replacement
of arginine by histidine disrupts oligomerisation in a pH-
dependent manner, making the domain unable to oligomer-
ise in conditions of slightly elevated pH [8,9]. Although
biological dependence upon pH has not been demonstrated
thus far, it is plausible that the p.R337H mutant protein
operates as a conditional mutant that loses its function only
in cells undergoing a small increase in intracellular pH.
This type of change may be occurring in cells undergoing
programmed cell death during developmental tissue re-
modelling, such as in the peri-natal adrenal cortex.
Subsequent to the initial studies on childhood ACC,
studies of families with LFS traits have shown that the mu-
tation predisposes individuals to a wide range of cancers.
Similar to the canonical forms of LFS, the most common
cancers in p.R337H carriers are pre-menopausal breast can-
cer and sarcoma before age 45 [10-12]. However, the pene-
trance of the disease in p.R337H carriers appears to
be significantly lower than in carriers of germline TP53
mutations occurring in the DNA-binding domain. TP53
haplotyping of 12 apparently unrelated p.R337H-positive
families showed that the mutation occurred on the same al-
lele, demonstrating a founder effect [12,13].
Population-based studies indicate that the carrier rate
in southern and southeastern Brazil is of approximately
0.3% [14,15]. Assuming Hardy-Weinberg equilibrium,
mutant homozygotes (i.e., individuals who inherited one
mutant allele from each parent) are predicted to occur
with a frequency of approximately 1 in every 455.000 live
births based on this relatively high carrier prevalence.
Studies in TP53-deficient mice have shown a reduced
exercise capacity associated with a lower mitochondrialdensity in skeletal muscle [16-18]. TP53-deficient mice
did not respond to a 5-week aerobic training protocol,
indicating that p53 is required to complete the adaptive
changes in aerobic metabolism that are necessary for in-
creasing exercise capacity in response to training [17].
However, no information is currently available on the
impact of TP53 deficiency on the exercise capacity of
patients with germline TP53 mutations. Here we report
the diagnosis, follow-up and monitoring of exercise ca-
pacity in a young patient homozygous for the germline
TP53 p.R337H mutation.
Case presentation
A previously healthy female child of European (Portuguese
and Spanish) descent was referred to a paediatrician at
11 months of age with a history of increased appetite, sig-
nificant weight gain in the past three months, and signs of
virilisation. Review of the family history revealed second-
and third-degree relatives diagnosed with cancer consis-
tent with a LFL tumour pattern. Both parents were healthy,
with no personal history of cancer, and were unrelated.
On admission, the patient weighed 14.550 kg (> the 95th
percentile) and measured 83 cm (> the 95th percentile).
Blood pressure was 130/90 mmHg, and physical examin-
ation revealed a round “moon-like” face, excess facial and
body hair, pubarche and clitoromegaly, facial acne and an
abdominal mass on palpation.
Laboratory evaluations showed normal serum sodium,
potassium, calcium, phosphorus and creatinine. Hormo-
nal evaluations showed very high levels of androgens:
dehydroepiandrosterone sulphate (DHEAS) > 1000 μg/dL
(nl: 2-274 μg/dL), dehydroepiandrosterone > 30 ng/ml
(nl: < 2,5 ng/ml), testosterone 9.61 ng/dL (nl: < 0,05 ng/dL),
androstenedione > 10 ng/dL (nl: < 0,5 ng/ml), 17-alpha-
hydroxyprogesterone 8,88 ng/ml (nl: < 1,0 ng/ml), proges-
terone 4803 pg/ml (nl: < 800 pg/ml), morning cortisol
37 μg/dl (nl: 4,3-22,4 μg/dl), and midnight cortisol 32 μg/dl
(nl: < 1,0 μg/dl). Urinary free cortisol was normal: 80 μg/
24 h (nl: 20 – 90 μg/24 h), and ACTH was undetectable.
Bone age was assessed using the Greulich-Pyle method and
was found to be 24 months (SD = 2.4 months) despite a
chronological age of 14 months. Abdominal computerised
tomography identified a heterogeneous adrenal mass (4.5 ×
3.4 × 3.0 cm), which was excised without disturbing the
adrenal capsule. Surgical margins were negative, and histo-
pathological examination of the tumour tissue confirmed
the diagnosis of an anaplastic adrenal cortical tumour
(4.5 × 4.0 × 2.8 cm) weighing 27 gram.
At the age of 6 years, the patient was recruited for a
TP53 mutation prevalence study, which was offered to
all patients diagnosed or treated for paediatric tumours
of the LFS cancer spectrum at Hospital de Clínicas de
Porto Alegre from 1998 to 2010 (IRB# 08022). The pa-
tient was found to be homozygous for a germline TP53
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described below). The patient is under follow-up with
paediatric oncology, endocrinology, and cancer genetics
specialists. Ninety-six months after the diagnosis of the
ACC (at age 9 years), the patient appears healthy and has
adequate cognitive and psychomotor development. There
is currently no clinical or laboratory evidence of endocrine
derangements. After diagnosis, the patient was followed
by the paediatric oncology team through age 8 years,
according to the NCCN [19] guidelines. Full body and
brain magnetic resonance imaging (Figure 1) and cardio-
pulmonary exercise testing (Table 1) were performed at
age 8 years and 8 months. MRI failed to detect any suspi-
cious proliferative lesions, and the results of the cardiopul-
monary exercise test were within the normal reference
for 9-year-old girls; these results indicated that there
was no major exercise capacity deficiency in this patient.(a)
(b) (c)
Figure 1 Pedigree of the homozygous TP53 p.R337H/p.R337H patient an
Dx: age at diagnosis; WT: wild-type (a) Pedigree of the homozygous TP53 p.R33
symbols; the arrow indicates the proband; current age is indicated in parenthes
homozygosity for the A allele at genomic nucleotide number 16901 and from hA detailed description of the evaluations performed is
presented below.
Evaluation of functional capacity
At the age of 8 years and 8 months, the patient was
submitted to maximal exercise testing on an electro-
magnetically braked cycle ergometer (ER-900, Ergoline,
Jaeger, Würzburg, Germany) at 60 revolutions per min.
She was not receiving any medication. Hormonal evalua-
tions showed undetectable androgens, and bone age
corresponded to chronological age. The patient first
exercised for 3 min with no load; the work rate was then
increased by 10 W per min until volitional fatigue, indi-
cated by the inability to maintain the pedalling rate above
40 revolutions per min. A twelve-lead electrocardiogram
(Nihon Khoden Corp.,Tokyo, Japan) was continuously
monitored, and expired gases were collected breath-by-(d)
d TP53 Exon 10 sequencing results from the proband and parents.
7H/p.R337H patient. Relatives affected by cancer are shown with blackened
is. TP53 exon 10 sequencing results from the proband (b) demonstrating
er parents (c, d) showing heterozygosity at the same nucleotide position.
Table 1 Anthropometric data and results of the
cardiopulmonary exercise test for the TP53 p.R337H
homozygous patient at the age of 8 years and 8 months
Variable Measured Percentage
of predicted*
Weight (kg and %) 37.5 114
Height (cm and %) 144.5 105
Body mass index (kg/cm2 and %) 17.9 96
Peak power output (W and %) 80 101
Peak heart rate (bpm and %) 164 88
Peak VO2 (mL/kg.min and %) 35.9 85
VE/VCO2 slope (ratio and %) 25.2 78
Peak respiratory exchange ratio
(ratio and %)
1.11 97
Peak O2 saturation (%) 98 NA
Anaerobic threshold (mL/kg.min and %) 24.9 96
Peak stroke volume (mL/min) 46 NA
Peak cardiac output (L/min) 7.62 NA
Legend: *Predicted values for girls on the cycle ergometer, according to Ten
Harkel et al. 2011; NA: reference value not available; bpm: beats per minute;
VO2: oxygen uptake; VE: minute ventilation; VCO2: carbon dioxide production.
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VIASYS, Healthcare GmbH, Würzburg, Germany). Peak
values for oxygen uptake and respiratory exchange ratio
are reported as the highest 20 s mean values. The anae-
robic threshold (also referred to as the first ventilatory
threshold) was determined by review of the gas exchange
curves; the anaerobic threshold is defined as the oxygen
uptake at which the ventilatory equivalent for oxygen in-
creased systematically without an incremental change
in the ventilatory equivalent for carbon dioxide [20]. The
per minute ventilation/carbon dioxide output slope was
calculated using a linear regression analysis based on all
points of the incremental exercise [20]. Before and dur-
ing the exercise tests, cardiac output and stroke volume
were estimated non-invasively by impedance cardiography
(PhysioFlow PF07 Enduro, Manatec Biomedical, Paris,
France) as previously described [21]. Arterial oxygen satu-
ration was measured by finger oximetry (Takaoka Oxicap,
São Paulo, Brazil).
The results of the cardiopulmonary exercise test, in-
cluding the percentage of the predicted values for girls
[22], are presented in Table 1. The test was stopped due
to fatigue, with the peak heart rate and the peak respi-
ratory exchange ratio compatible with maximal effort.
Compared to the reference values, the patient presented
peak power output, peak oxygen uptake, and anaerobic
threshold consistent with preserved exercise capacity
(85 to 101% of predicted). The minute ventilation/carbon
dioxide output slope indicated normal ventilatory efficiency.
Stroke volume and cardiac output increased appropriately
during the incremental exercise test [23].Genetic analyses
Genomic DNA was obtained from (a) peripheral lympho-
cytes and fibroblasts using the Ilustra™ blood genomic
Prep Mini spin Kit (GE Healthcare, Madison, WI, USA) as
described by the manufacturer and from (b) formalin-fixed
paraffin-embedded tumour tissues using the QIAmp DNA
FFPE Tissue Kit (Qiagen, Hilden, Germany). DNA from
lymphocytes was screened for the TP53 p.R337H mutation
with allele-specific TaqManW probes (Applied Biosystems,
Foster City, CA, USA) using a MX 3000P™qPCR System -
Stratagene (Agilent Technologies Inc., Santa Clara, CA,
USA) and analysed using the Stratagene MxPro qPCR
Software. Presence of the mutation was confirmed by
PCR-RFLP using the restriction enzyme HhaI [14] and by
bidirectional gene sequencing of exon 10 using an ABI
PRISM 3130XL Genetic Analyzer (Applied Biosystems,
Foster City, CA, USA) following the sequencing protocol
described in the IARC TP53 database [24]. All genotyping
results were confirmed in at least two independent ana-
lyses. The only nucleotide detected at position 17588 was
A (CAC at codon 337, homozygote for the mutant allele)
in both the genomic DNA from peripheral lymphocytes
and fibroblasts and in the DNA extracted from micro-
dissected, formalin-fixed, paraffin-embedded ACC tissues.
Both the father and mother were found to be heterozygous
TP53 p.R337H carriers (Figure 2). Direct sequencing of
the entire TP53 coding region (exons 2-11) of the index
case and the parents did not detect other germline muta-
tions. Allele-specific PCR (ASO PCR) for TP53 SNP179
identified the proband as well as both parents as carriers of
the p.R337H Brazilian founder allele described by Garritano
et al. (2010) [12]. The presence of the Brazilian founder p.
R337H haplotype (A3) was verified in mutation-positive
samples, as previously described [12], by both ASO-PCR
and Nested-PCR used to analyse SNP28 (rs9894946) from
a panel of 29 intragenic SNPs. Because this SNP is identical
in haplotypes A1 and A3, all cases were further genotyped
for SNP15 (rs1642785) and SNP18 (rs1800370) by direct
sequencing. Multiplex ligand probe amplification (MLPA),
used to assess the presence of TP53 gene deletions,
was performed in the index case using genomic DNA
from leukocytes and fibroblasts and the SALSA P056
kit (MRC, Amsterdam, The Netherlands), according to
the manufacturer’s instructions. No TP53 deletion was
identified in the germline. With these results, a homozy-
gous genotype at position 16901 was inferred, although
uniparental disomy could not be definitively excluded.
We were unable to confirm whether one of the mutant
alleles was lost in the tumor, due to limited availability of
tumoral tissue.
Discussion
We describe a patient who is a homozygous carrier of a
germline TP53 mutation, p.R337H, having inherited the
(a) (b) (c)
Figure 2 Whole body magnetic resonance imaging of the TP53 p.R337H homozygous patient. (a) Coronal plane T1 Turbo Spin Echo (TSE)
weighted image, (b) coronal plane Turbo Short TI Inversion Recovery (STIR) image and (c) coronal plane image recorded after diffusion-weighted
imaging (DWI) on the axial plane with further maximum intensity projection (MIP) reconstruction. Imaging: Brain and whole body magnetic
resonance imaging studies were conducted using a 1.5 Philips Achieva (Philips Healthcare, Latham, NY, USA) series scanner following the
protocols described [25,26], with modifications. The diffusion-weighted imaging with body background suppression protocol using a free-
breathing technique, as described [27], was applied. In brief, T1 Turbo Spin Echo (T1 TSE) weighted images (T1) and Short TI Inversion. Recovery
(STIR) were performed on the coronal plane, and diffusion-weighted imaging (DWI) was performed on the axial plane with further maximum
intensity projection (MIP) reconstruction on the coronal plane. We used the body coil and asked for the breath to be held for the thorax and
abdomen image acquisitions. Restricted diffusion was observed in the area corresponding to the bone marrow of the lower limbs but followed
the expected pattern for age, as described previously [28].
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rently aged 9 years, developed ACC at age 11 months and
has been under clinical follow-up for other health out-
comes, including cancers of the Li-Fraumeni spectrum,
since that time. At age 9 years, the patient was healthy, with
normal development, normal cardiopulmonary/exercising
capacity and no suspicious proliferative lesions detectable
using standard whole-body MRI.
In western Europe, it has been estimated that germline
TP53 mutations spontaneously occur at a rate of 1:5,000
births [29]. Approximately 50% of mutation carriers
develop cancer by age 30. Carriage of two mutant alleles
in the classic DNA-binding domain region of the gene
(either through de novo mutation on both alleles or
through inheritance of a mutant from both paternal and
maternal sides) is therefore predicted to be an extremely
rare event; indeed, there have been no reports of such
an event. In Brazil, however, the existence of a founder
mutation, p.R337H, which is present in approximately0.3% of the dense population in the southern and south-
eastern regions of the country, make the occurrence of
homozygosity for germline TP53 mutations more likely
than anywhere else in the world. Prior to this report, homo-
zygosity for p.R337H had been observed in one subject in a
study of 55 Brazilian paediatric and adult patients with ap-
parently sporadic ACC. That patient, a girl diagnosed with
ACC at 12 months of age and whose parents were un-
affected carriers, was healthy and had not developed an-
other cancer at age 10 years [30, Latronico and Fragoso,
personal communication 2011].
Several studies have shown that germline mutations
in cancer predisposition genes may have a dose effect,
resulting in a more severe phenotype in homozygotes
than in heterozygotes. For example, the heterozygous
state of the CHEK2 1100delC variant, which predisposes
carriers to breast cancer, is associated with an OR of 1.5-
3.0 (corresponding to a lifetime risk of 20-25%), while
the homozygous state is associated with a greater than
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general population [31,32]. Furthermore, several cancer-
predisposing mutations in tumour-suppressor genes display
different phenotypes in heterozygotes and homozygotes.
This is the case for mutations in the PALB2, BRIP1 and
ATM genes, where heterozygotes have an increased lifetime
risk of breast cancer, and homozygotes are diagnosed with
multisystemic genetic syndromes (Fanconi’s anaemia for
the first 2 genes and ataxia-telangiectasia for the latter).
There are also situations where homozygous and heterozy-
gous states for a mutation in the same gene are each associ-
ated with different genetic syndromes, such as the Lynch
(LS) and Childhood Cancer (CCS) syndromes associated
with heterozygous and homozygous germline mutations in
the MMR genes [33,34].
In the present case, our observations do not support the
hypothesis that inheritance of two mutant TP53 alleles may
lead to a compound phenotype with increased risk for early
onset cancer. It is possible that the absence of cumulative
effects is due to the particular structural properties of the p.
R337H mutant protein. Based on the structural analysis of
a peptide encoding the oligomerisation domain, it has been
shown that replacement of arginine by histidine at position
377 perturbs the formation of a hydrogen bond that links
R377 on one p53 monomer to D352 on another p53 mono-
mer, thus forming a dimer [8]. At pH 7, histidine at position
377 retains the capacity to donate a H-bond. However,
at pH 8, this capacity is lost, thus preventing dimerisa-
tion at slightly elevated pH levels. In the present case, we
speculate that the proteins encoded by the two mutant
alleles can form dimers in neutral pH conditions, which
also occurs between one mutant and one wild-type mono-
mer in patients who inherit only one mutant p.R337H
allele. However, upon a small pH increase, the hydrogen
bonds between the monomers, which form the homodimer
consisting of the two mutant proteins, would be expected
to break.
Recent experimental studies have shown that p53 plays
a critical role in controlling cell bioenergetics and, spe-
cifically, mitochondrial metabolism [18]. In the mouse,
lack of p53 leads to impaired cardiorespiratory fitness
and loss of aerobic competence. Mice lacking functional
p53 show a decrease in maximum exercise capacity and
are less responsive to the effects of training than their
p53-competent counterparts [16,17]. However, such effects
have not been documented in humans thus far. The results
of the cardiopulmonary exercise test performed here indi-
cate that, despite carrying two TP53 mutant alleles, our
patient has preserved functional capacity, as demonstrated
by peak power output, peak oxygen uptake, and an anaer-
obic threshold within the limits of normality [21]. More-
over, ventilatory efficiency and hemodynamic responses
to exercise were also normal. If mitochondrial abnormal-
ities were to be present in our patient, we would expectto observe an early anaerobic threshold, reduced peak oxy-
gen uptake, and ventilatory inefficiency. Because individ-
uals with metabolic abnormalities, such as patients with
McArdle’s disease, may present hyperventilation during
exercise without blood lactate accumulation [35], a pre-
served ventilatory anaerobic threshold, as observed in our
patient, may not assure normal muscle oxidative metabo-
lism. However, normal maximal exercise capacity and a
normal anaerobic threshold are strong indicators of pre-
served muscular oxidative capacity. In healthy individuals,
there is a strong association between muscle respiratory
capacity and the anaerobic threshold [36]. Although an in-
fluence of previous or current androgen excess on energy
metabolism in this patient cannot be excluded, such an
influence is unlikely because cardiovascular function was
assessed many years after the normalisation of the hor-
mone levels and bone age results were normal. Therefore,
the cardiopulmonary exercise test results for our patient
indicate that inheritance of two mutant TP53 p.R337H
alleles does not appear to affect energy metabolism in
humans by the age of 10 years.
Conclusion
The current report is the first clinical description and
documentation of aerobic functional capacity of a pa-
tient who carries two mutant TP53 alleles and no wild-
type allele. Our results support the hypothesis that TP53
p.R337H, the most common TP53 mutation ever de-
scribed in any population, is a conditional mutant. Fur-
thermore, our observations over a long period of clinical
follow-up do not support the hypothesis that p.R337H
homozygotes may have a more severe disease phenotype
than heterozygote carriers of the same mutation. How-
ever, the particular genetic status of these patients will
require careful surveillance for lifetime cancer risk and
for effects on metabolic capacity later in life.
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